Straticyte™ Observational Study Registered on

MaRS Discovery District, Toronto, ON; November 10, 2020 – Proteocyte AI, a personalized medicine and diagnostics company located in MaRS Centre, Toronto, ON, announces today that the company has registered an observational study on, a database of privately and publicly funded clinical studies conducted around the world. The study, titled Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment, has been assigned the Identifier: NCT04622462.

Dr. Mark Darling, a professor in Pathology at Western University (London, ON) and the principal investigator of this observational study says: “the focus of oral pathologists for decades has been centred on the predictive value of oral epithelial dysplasia presence and grade to determine progression risk to oral cancer. Except for the most advanced category, severe dysplasia, grading of dysplastic lesions has failed to provide reliable prognostic information. Investigating prognostic markers independent from dysplasia and grade (such as in this study) could lead to more effective prognostic indicators.”

Oral cancer is the 8th most common cancer in North America, affecting over 50,000 in the United States and 5,000 people in Canada annually. Early detection of oral cancer and precancerous lesions at high-risk of developing oral cancer is known to improve survival.

Through this study, the company hopes to demonstrate that Straticyte could be used in the clinical community setting to provide adjunctive and quantitative information to the standard of care, for better management of patients with clinically suspicious oral lesions.

About Proteocyte

Proteocyte AI is a personalized medicine and diagnostics company located in MaRS Centre, Toronto, ON. Proteocyte’s products help tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.